Garrison Financial Corp increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.3% during the second quarter, Holdings Channel reports. The firm owned 11,675 shares of the company’s stock after buying an additional 145 shares during the period. Garrison Financial Corp’s holdings in Novo Nordisk A/S were worth $501,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after buying an additional 2,463,300 shares during the period. Bank of America Corp DE increased its position in Novo Nordisk A/S by 3.2% in the first quarter. Bank of America Corp DE now owns 12,102,582 shares of the company’s stock worth $414,876,000 after buying an additional 380,536 shares during the period. Fisher Asset Management LLC increased its position in Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after buying an additional 1,331,992 shares during the period. State Street Corp increased its position in Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after buying an additional 5,584,680 shares during the period. Finally, Sustainable Growth Advisers LP increased its position in Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock worth $139,482,000 after buying an additional 598,644 shares during the period. Institutional investors and hedge funds own 6.40% of the company’s stock.

Novo Nordisk A/S (NVO) opened at 45.81 on Friday. The stock has a market cap of $113.62 billion, a P/E ratio of 18.74 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $47.98. The stock has a 50 day moving average price of $42.76 and a 200-day moving average price of $38.81.

The business also recently announced an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be issued a $0.336 dividend. The ex-dividend date is Friday, August 18th. This represents a yield of 1.07%. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 36.00%.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/12/garrison-financial-corp-has-501000-position-in-novo-nordisk-as-nysenvo.html.

NVO has been the subject of a number of analyst reports. Zacks Investment Research downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. BidaskClub downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Finally, TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $53.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.